Recent Updates
Recently added Catalysts
BIOA Negative Sentiment Score: 25/100

BIOAGE LABS, INC. (NASDAQ: BIOA) INVESTOR ALERT: Investors With Large Losses in BioAge Labs, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Key Takeaway: Bernstein Liebhard LLP has initiated a class action lawsuit on behalf of investors in BioAge Labs, Inc. (NASDAQ: BIOA), alleging misrepresentations related to its STRIDES Phase 2 clinical trial of azelaprag. The lawsuit claims the company did not adequately disclose relevant information regarding the trial's outcomes. Investors who purchased BioAge shares during the company's IPO are encouraged to discuss their rights and may seek to serve as lead plaintiffs. The deadline for filing papers is March 10, 2025.

Market Sentiment Analysis

CONCERNS & RISKS

  • A securities class action lawsuit has been filed against BioAge Labs for misrepresentations.
  • The lawsuit relates to the Company's clinical trial of azelaprag, raising concerns over its integrity.
  • Investors may have incurred large losses, prompting legal advice for recovery.

Full Press Release Details

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the stock of BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA) pursuant and/or traceable to the Company’s registration statement for the initial public offering held on or about September 26, 2024.
For more information, submit a form at BioAge Labs, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) 951-2030.
According to the lawsuit, BioAge made misrepresentations concerning its ongoing STRIDES Phase 2 clinical trial of azelaprag, its lead product candidate, in combination with GLP-1R agonists to establish proof of concept for enhanced weight.
If you wish to serve as lead plaintiff for the Class, you must file papers by March 10, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP

Tags

class action lawsuit

Frequently Asked Questions

What is the BioAge Labs securities class action lawsuit about?

Investors filed a lawsuit claiming BioAge misrepresented its clinical trial results.

When must I file as a lead plaintiff for the class?

Papers must be filed by March 10, 2025, to serve as lead plaintiff.

Do shareholders incur fees for participating in the lawsuit?

No, all representation is on a contingency fee basis with no fees for shareholders.

How can I contact Bernstein Liebhard LLP for more information?

You can email Peter Allocco at pallocco@bernlieb.com or call (212) 951-2030.

What is the lead product candidate of BioAge Labs?

BioAge’s lead product candidate is azelaprag, tested in a Phase 2 trial.

Last updated: Jan 8, 2025